Insurance Gaps Push Patients to Ketamine Access Funds

The Coverage Wall Most Ketamine Patients Hit

A new report from The Daily Northwestern spotlights a Chicago-based foundation stepping in to fund ketamine treatment for patients with depression who cannot afford out-of-pocket costs — and who cannot afford to wait for insurers to catch up. The story puts a human face on a structural problem that clinicians and patients have quietly navigated for years: ketamine is clinically transformative for treatment-resistant depression, but the vast majority of U.S. health insurers still classify it as experimental and refuse to reimburse it.

The foundation profiled is helping bridge that gap directly, covering treatment costs for qualifying patients. While the article focuses broadly on ketamine therapy, the access crisis it describes is especially acute for patients considering at-home options like ketamine troches — where the out-of-pocket model is already the norm, and where cost-sensitive patients are most likely to delay or discontinue care.

Why Insurance Still Refuses to Budge

Ketamine has been FDA-approved as an anesthetic since 1970, but its use in psychiatric treatment falls into an off-label category that insurers use to justify non-coverage. The one exception — esketamine (Spravato), a nasal spray derived from ketamine — carries FDA approval specifically for treatment-resistant depression and major depressive disorder with suicidal ideation. Some plans cover Spravato, but it requires in-office administration, costs significantly more than compounded alternatives, and still faces frequent prior authorization denials.

Compounded ketamine troches sit even further outside the insurance framework. Because they are prepared by compounding pharmacies rather than manufactured by a brand-name drug company, they have no FDA-approved indication and no reimbursement pathway under most commercial plans or Medicare. That means the full cost — consultation, prescription, and ongoing troche supply — falls on the patient. For many people battling severe or chronic depression, that financial burden arrives at exactly the moment they are least equipped to absorb it.

What the Troche Access Picture Looks Like in Practice

Ketamine troches have emerged as one of the more accessible formats precisely because they eliminate the clinic visit. Patients dissolve a compounded lozenge sublingually at home, following a structured protocol established with their prescribing provider. Monthly troche costs typically run between $150 and $400 depending on dose, frequency, and compounding pharmacy — considerably less than IV infusion series, which can run $2,000 to $4,000 for a standard six-session course.

That lower price point has made troches the entry point for many patients priced out of infusion therapy. But "more affordable" is not the same as "affordable," particularly for individuals on disability income, those without employer-sponsored insurance, or patients in the middle of a depressive episode who are already struggling with daily functioning. The Chicago foundation's model — direct financial assistance tied to clinical need — addresses exactly that population.

It also signals something broader: the philanthropic and nonprofit sectors are beginning to recognize ketamine access as a health equity issue, not just a billing inconvenience. That framing matters for how policy conversations will evolve over the next few years.

Where Advocacy and Reimbursement May Be Heading

There is incremental movement on the insurance front. A handful of state Medicaid programs have begun covering ketamine infusions under specific clinical criteria. Some commercial insurers have issued coverage policies for IV ketamine when documented treatment resistance meets a defined threshold. These are narrow carve-outs, not broad access, but they represent a shift in the payer conversation from "never" to "under what conditions."

For compounded troches, the path to reimbursement is more complicated. Compounded medications operate under a different regulatory framework, and insurer coverage of compounded drugs remains uncommon even for conditions where the underlying drug is covered. The most realistic near-term scenario for troche patients is not insurance reimbursement — it is expanded access through patient assistance programs, sliding-scale clinic fees, HSA and FSA eligibility (which does apply to ketamine treatment costs in most cases), and foundations like the one featured in this report.

Providers and patients navigating this landscape should document treatment history thoroughly. If an insurer does begin covering ketamine for treatment-resistant depression, patients who can demonstrate a documented failure of multiple antidepressant trials will be better positioned to qualify. That documentation is worth maintaining regardless of current coverage status.

The Bottom Line for Troche Patients

The Chicago foundation's work is a meaningful stopgap, but it also underscores how far the coverage landscape still needs to travel. Ketamine troches occupy a practical middle ground in the treatment spectrum — more flexible and less expensive than infusions, more personalized than a fixed-dose nasal spray — but that value proposition only holds if patients can sustain access over time. Cost-driven discontinuation is a real clinical risk in a treatment that works best with consistent, protocol-driven use.

Stories like this one help normalize the conversation about ketamine affordability and push the issue into public view. For patients, providers, and advocates, visibility is the first step toward structural change. Read the original reporting at The Daily Northwestern.